25 studies found for:    pleural plaque OR pleural effusion OR asbestosis OR mesothelioma | Open Studies | NIH, U.S. Fed
Show Display Options
RSS Create an RSS feed from your search for:
pleural plaque OR pleural effusion OR asbestosis OR mesothelioma | Open Studies | NIH, U.S. Fed
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Condition: Mesothelioma
Intervention:
2 Recruiting SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Conditions: Mesothelioma;   Adenocarcinoma of Lung;   Pancreatic Neoplasms
Interventions: Drug: Pentostatin;   Drug: Cyclophosphamide;   Biological: SS1(dsFv)PE38 - lot 073I0809;   Biological: SS1(dsFv)PE38 - lot FIL129J01
3 Recruiting Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
Conditions: Advanced Peritoneal Malignant Mesothelioma;   Advanced Pleural Malignant Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Solid Neoplasm;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pleural Mesothelioma;   Thymoma
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Pemetrexed Disodium;   Other: Pharmacological Study
4 Recruiting Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium;   Other: clinical observation
5 Recruiting Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Peritoneal Malignant Mesothelioma;   Pleural Biphasic Mesothelioma;   Pleural Epithelioid Mesothelioma;   Pleural Malignant Mesothelioma;   Pleural Sarcomatoid Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study
6 Recruiting Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Advanced Pleural Malignant Mesothelioma;   HLA-A*0201 Positive Cells Present;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pleural Mesothelioma
Interventions: Biological: Aldesleukin;   Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
7 Recruiting Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Pleural Epithelioid Mesothelioma;   Pleural Malignant Mesothelioma
Interventions: Radiation: Hypofractionated Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
8 Not yet recruiting Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Conditions: Recurrent Pleural Malignant Mesothelioma;   Stage IV Pleural Mesothelioma
Intervention: Drug: Nintedanib
9 Recruiting Clinical and Histopathologic Characteristics of BAP1 Mutations
Conditions: Malignant Pleural Mesothelioma (MPM);   Choroidal Nevus;   Primary Uveal Melanoma (UM);   Metastatic Uveal Melanoma (UM);   Renal Cell Carcinoma;   Cholangiocarcinoma
Intervention: Other: tumor specimens
10 Recruiting Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Conditions: Pulmonary Metastases From Cancers;   Mediastinal or Chest Wall Neoplasms;   Malignant Pleural Mesotheliomas NOS;   Esophageal Cancers NOS;   Lung Cancer NOS
Intervention:
11 Recruiting Mithramycin for Lung, Esophagus, and Other Chest Cancers
Conditions: Lung Cancer;   Esophageal Cancer;   Mesothelioma;   Gastrointestinal Neoplasms;   Breast Cancer
Intervention: Drug: Mithramycin
12 Not yet recruiting Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Metastatic Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Solid Neoplasm;   Stage III Mesothelioma;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
13 Recruiting 18F-FSPG PET/CT for Cancer Patients on Therapy
Conditions: B-Cell Neoplasm;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Renal Cell Cancer;   Progesterone Receptor Negative;   Stage III Mesothelioma;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Triple-Negative Breast Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Fluorine F 18 L-glutamate Derivative BAY94-9392;   Procedure: Positron Emission Tomography;   Procedure: Magnetic Resonance Imaging
14 Recruiting Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue
Conditions: Thymus Tumors;   Mesothelioma;   Non- Small Cell Lung Cancer;   Small Cell Lung Cancer
Intervention:
15 Recruiting Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Conditions: Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Other: cytology specimen collection procedure;   Procedure: therapeutic procedure;   Drug: targeted therapy;   Other: laboratory biomarker analysis
16 Recruiting Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: metformin hydrochloride;   Drug: placebo;   Other: laboratory biomarker analysis
17 Recruiting Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis
Condition: Pleural Effusion
Interventions: Other: Manometry-guided thoracentesis;   Other: Symptom-guided thoracentesis
18 Recruiting Electrical Impedance Imaging of Patients on Mechanical Ventilation
Conditions: Pneumothorax;   Pulmonary Contusion;   Pleural Effusion;   Pulmonary Edema;   Atelectasis;   Hyperinflation;   Emphysema;   Acute Respiratory Distress Syndrome
Interventions: Device: Mechanical Ventilation;   Device: CT Scan
19 Recruiting Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Conditions: Liver Cancer;   Anxiety Disorder;   Depression;   Small Cell Lung Cancer;   Extrahepatic Bile Duct Cancer;   Malignant Mesothelioma;   Pancreatic Cancer;   Esophageal Cancer;   Gastric Cancer;   Non-small Cell Lung Cancer
Intervention: Other: Early palliative care
20 Recruiting αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface;   Malignant Peritoneal Mesothelioma;   Peritoneal Carcinomatosis
Interventions: Biological: DC vaccine;   Drug: Celecoxib;   Drug: Interferon Alfa-2b;   Biological: rintatolimod

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years